JP2024538791A - ＩｇＥ介在性疾患の治療 - Google Patents

ＩｇＥ介在性疾患の治療 Download PDF

Info

Publication number
JP2024538791A
JP2024538791A JP2024522375A JP2024522375A JP2024538791A JP 2024538791 A JP2024538791 A JP 2024538791A JP 2024522375 A JP2024522375 A JP 2024522375A JP 2024522375 A JP2024522375 A JP 2024522375A JP 2024538791 A JP2024538791 A JP 2024538791A
Authority
JP
Japan
Prior art keywords
ige
antibody
seq
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024522375A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024538791A5 (https=
Inventor
クオ，ビー－ション
リィ，チャオ－フン
リィ，ユワン－フォン
リン，シュージーン
イー ワン，チャン
Original Assignee
ユナイテッド バイオファーマ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユナイテッド バイオファーマ インコーポレイテッド filed Critical ユナイテッド バイオファーマ インコーポレイテッド
Publication of JP2024538791A publication Critical patent/JP2024538791A/ja
Publication of JP2024538791A5 publication Critical patent/JP2024538791A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2024522375A 2021-10-12 2022-10-12 ＩｇＥ介在性疾患の治療 Pending JP2024538791A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163254729P 2021-10-12 2021-10-12
US63/254,729 2021-10-12
PCT/CN2022/124777 WO2023061390A1 (en) 2021-10-12 2022-10-12 Treatment of ige-mediated diseases

Publications (2)

Publication Number Publication Date
JP2024538791A true JP2024538791A (ja) 2024-10-23
JP2024538791A5 JP2024538791A5 (https=) 2025-10-20

Family

ID=85981469

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024522375A Pending JP2024538791A (ja) 2021-10-12 2022-10-12 ＩｇＥ介在性疾患の治療

Country Status (7)

Country Link
US (1) US20230122862A1 (https=)
EP (1) EP4416176A4 (https=)
JP (1) JP2024538791A (https=)
KR (1) KR20240082392A (https=)
CN (1) CN118119641A (https=)
TW (1) TW202332691A (https=)
WO (1) WO2023061390A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024050455A2 (en) * 2022-08-31 2024-03-07 Heitmeyer Jamie Nicole Anti-rhd antibodies for treating inflammatory dermal condition
WO2025015286A2 (en) * 2023-07-13 2025-01-16 Inhibrx Biosciences, Inc. Ige binding proteins and uses thereof
KR20260042217A (ko) 2023-07-13 2026-03-30 인히브릭스 바이오사이언스, 인크. IgE 결합 단백질 및 이의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012204078A1 (en) * 2007-02-15 2012-08-02 Astrazeneca Ab Binding members for IgE molecules
KR20140119777A (ko) * 2012-01-31 2014-10-10 제넨테크, 인크. 항-ig-e m1'' 항체 및 그의 사용 방법
DK3157951T3 (da) * 2014-06-17 2020-08-17 Academia Sinica Humaniserede anti-ige-antistoffer, der tværbinder cd23 på b-lymfocytter, men ikke sensibiliserer mastceller
JP6068582B2 (ja) * 2015-08-07 2017-01-25 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Ｂリンパ球上のヒトｍＩｇＥに結合可能な抗ＣεｍＸ抗体
GB201610198D0 (en) * 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
WO2019085902A1 (en) * 2017-10-31 2019-05-09 Fountain Biopharma Inc. Treating ige-mediated allergic diseases

Also Published As

Publication number Publication date
WO2023061390A1 (en) 2023-04-20
EP4416176A1 (en) 2024-08-21
TW202332691A (zh) 2023-08-16
KR20240082392A (ko) 2024-06-10
EP4416176A4 (en) 2025-12-31
CN118119641A (zh) 2024-05-31
US20230122862A1 (en) 2023-04-20

Similar Documents

Publication Publication Date Title
US20250059270A1 (en) Il-6 antibodies
EP3808774B1 (en) Human il-4r binding antibody, antigen binding fragment thereof, and medical use thereof
EP3489258A1 (en) Il-6 antagonists and uses thereof
CA3044851A1 (en) Methods of treating inflammatory conditions
JP2024538791A (ja) ＩｇＥ介在性疾患の治療
EP4200018B1 (en) Anti-par-2 antibodies and methods of use thereof
KR20120075457A (ko) 톨-유사 수용체 2에 대한 인간화 항체 및 이의 용도
JP2013503626A (ja) グルカゴン受容体に対する抗体と、それらの使用
KR20210099053A (ko) Vegf 및 il-1베타에 결합하는 항체 및 이의 사용 방법
WO2013103783A1 (en) Murine il-13 antibodies
HK40115557A (en) Anti-par-2 antibodies and methods of use thereof
HK40027816A (en) Improved il-6 antibodies
HK40102410A (en) Improved il-6 antibodies
JP2024541576A (ja) 新規特異的アンタゴニスト抗ＳＩＲＰｇ抗体
HK40095177B (en) Anti-par-2 antibodies and methods of use thereof
HK40095177A (en) Anti-par-2 antibodies and methods of use thereof
HK1244008B (en) Improved il-6 antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251009

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251009